arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Hemab Therapeutics Holdings, Inc.

COAG
$49.50 ▼ -2.56 (-4.92%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
3 Visible periods
20 Metrics
Peer-ranked Benchmarks
Price Chart
insights
Verdict pending

Sync financial data to generate a health grade for this company.

auto_awesome

Analytical Summary

Review the statement evidence below to form a view on COAG.

Market Cap $46.8M
Dividend Yield
Revenue Growth
Op. Margin
ROIC 11.9%
FCF / Share $-22.93
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

3-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-22.69M
↓ -48.2%
FCF / Share Free cash flow per share
$-22.93
↓ -66.3%

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago